Novartis Farma S.p.A.

Novartis Farma S.p.A. is active in clinical research focused on chronic myeloid leukaemia, with interest in disease control, molecular response, and long-term management of patients after treatment consolidation.

• Chronic myeloid leukaemia
• Major molecular response
• Treatment-free remission

The sponsor’s research activity in this area centres on maintaining deep disease response and evaluating sustained remission strategies in a haematological malignancy setting.